

Claim 23. (Amended) The method of Claim 22, wherein the specific binding partner is covalently linked to a vehicle.

Please add new claims 38-45 as follows:

38. (New) The method of Claim 22, wherein the specific binding partner comprises the extracellular region of TACI (SEQ ID NO:15).

39. (New) The method of Claim 22, wherein the specific binding partner comprises the extracellular region of BCMA (SEQ ID NO:6).

CD 40. (New) The method of Claim 22, wherein the specific binding partner comprises the consensus region of TACI (SEQ ID NO:16).

41. (New) The method of Claim 22, wherein the specific binding partner comprises the consensus region of BCMA (SEQ ID NO:7).

42. (New) The method of Claim 22, wherein the specific binding partner comprises the TACI/BCMA extracellular consensus sequence (SEQ ID NO:13).

43. (New) The method of any of Claims 38-42, wherein the specific binding partner is covalently linked to a vehicle.

44. (New) The method of claim 43, wherein the vehicle is an Fc domain.

45. (New) The method of claim 3, wherein the specific binding partner comprises an anti-APRIL antibody.

REMARKS

Claims 3-4, 22-24, and 38-45 will be pending upon entry of the present amendment. Claim 22 has been amended to correct format and punctuation errors. Support for the term multimer is found in the specification, in part, from page 18, line 28 to page 19, line 6. Claim 23 has been amended so that it no longer depends upon cancelled claims. New claims 38-45 have been added. These new claims further